ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.

Date	Price Target	Rating	Analyst
3/6/2025	$2.00 → $3.00	Hold → Buy	Jefferies
12/19/2024	$12.00 → $2.00	Buy → Hold	Jefferies
3/8/2024	$10.00 → $14.00	Buy → Hold	Stifel
12/8/2023	$8.00 → $18.00	Hold → Buy	Jefferies
3/1/2022	$60.00 → $36.00	Buy	Stifel
12/22/2021	$65.00 → $25.00	Buy → Hold	Jefferies
9/30/2021	$106.00	Buy	Stifel

ALX Oncology Holdings Inc.

Peers

Recent Analyst Ratings for ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by SVP, FINANCE AND CAO Pinto Shelly

SEC Form 4 filed by Chief Medical Officer Sandler Alan B.

SEC Form 4 filed by Chief Financial Officer Shantharam Harish

SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Lettmann Jason

SVP, FINANCE AND CAO Pinto Shelly was granted 3,000 shares, increasing direct ownership by 3% to 90,352 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Lettmann Jason was granted 42,000 shares, increasing direct ownership by 25% to 212,270 units (SEC Form 4)

SVP, FINANCE AND CAO Pinto Shelly sold $633 worth of shares (550 units at $1.15), decreasing direct ownership by 0.63% to 87,352 units (SEC Form 4)

PRESIDENT & CSO Pons Jaume sold $1,525 worth of shares (1,326 units at $1.15), decreasing direct ownership by 0.23% to 579,388 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Lettmann Jason sold $2,483 worth of shares (2,159 units at $1.15), decreasing direct ownership by 1% to 170,270 units (SEC Form 4)

SEC Form 4 filed by Director Hemrajani Rekha

ALX Oncology Holdings Inc. SEC Filings

ALX Oncology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

SEC Form 10-Q filed by ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

ALX Oncology Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

SEC Form EFFECT filed by ALX Oncology Holdings Inc.

SEC Form DEF 14A filed by ALX Oncology Holdings Inc.

SEC Form S-3 filed by ALX Oncology Holdings Inc.

SEC Form 10-K filed by ALX Oncology Holdings Inc.